| MGFA-PIS . | Patients (%) . |
|---|---|
| Complete stable remission | 5 (14.7) |
| Pharmacological remission | 10 (29.4) |
| Minimal manifestations | 11 (32.3) |
| Unchanged | 4 (11.8) |
| Worse | 4 (11.8) |
| MGFA-PIS . | Patients (%) . |
|---|---|
| Complete stable remission | 5 (14.7) |
| Pharmacological remission | 10 (29.4) |
| Minimal manifestations | 11 (32.3) |
| Unchanged | 4 (11.8) |
| Worse | 4 (11.8) |
Median follow-up: 36 months.
MGFA-PIS: Myasthenia Gravis Foundation of America Post-Intervention Score.
| MGFA-PIS . | Patients (%) . |
|---|---|
| Complete stable remission | 5 (14.7) |
| Pharmacological remission | 10 (29.4) |
| Minimal manifestations | 11 (32.3) |
| Unchanged | 4 (11.8) |
| Worse | 4 (11.8) |
| MGFA-PIS . | Patients (%) . |
|---|---|
| Complete stable remission | 5 (14.7) |
| Pharmacological remission | 10 (29.4) |
| Minimal manifestations | 11 (32.3) |
| Unchanged | 4 (11.8) |
| Worse | 4 (11.8) |
Median follow-up: 36 months.
MGFA-PIS: Myasthenia Gravis Foundation of America Post-Intervention Score.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
